Nuvation Bio logo

Nuvation Bio

Brand

4.7

Company overview

Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai.
Founded in 2018
New York, New York, USA
220 employees (17 in marketing)
www.nuvationbio.com
100% recommend to a friend
61% positive business outlook

Salaries

Help build salary transparency at Nuvation Bio

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

3 open now

Headcount trend

Company growth over the last 12 months

Headcount +46.7% year over year

Funding

Total funding

$927M

Last raise

$150M

Post IPO Debt, 1 years ago

Funding history

Mar 2025

Post IPO Debt Nuvation Bio · $150M

Feb 2021

Post IPO Equity Nuvation Bio · $502M

Oct 2019

Series A Nuvation Bio · $275M

Audience

Monthly website visitors
21.8K
Month over month+36.9%
Quarter over quarter+31.2%
Top sourceDirect (44%)
Ad budget per month$13.2K
Average search rank38.7
Traffic source mix
Direct
44%
Search
39%
Social
9.8%
Referral
5.1%
Paid referral
2%

LinkedIn followers

Follower count and growth

Total followers

15.5K

12-mo growth

+75.8%

Monthly growth

+16.7%

News

Links

www.nuvationbio.comLinkedInCrunchbase
Glassdoor